Invitrogen

CD144 (VE-cadherin) Monoclonal Antibody (eBioBV13 (BV13)), PE-Cyanine7, eBioscience™

CD144 (VE-cadherin) Antibody in Flow Cytometry (Flow)

图: 1 / 22

CD144 (VE-cadherin) Antibody (25-1441-82) in Flow

Staining of bEnd-3 cells with 0.06 µg of Rat IgG1 K Isotype Control PE-Cyanine7 (Product # 25-4301-82) (blue histogram) or 0.06 µg of Anti-Mouse CD144 (VE-Cadherin) PE-Cyanine7 (purple histogram). Total viable cells were used for analysis.

Product Image Gallery

产品信息

25-1441-82

应用

建议稀释比

已发表文章

流式细胞分析 (Flow)

0.125 µg/test

查看9篇已发表文章 9篇已发表文章

产品规格

种属反应

Mouse

已发表种属

Human, Mouse

宿主/亚型

Rat / IgG1, kappa

分类

Monoclonal

类型

Antibody

克隆号

eBioBV13 (BV13)

偶联物

PE-Cyanine7 PE-Cyanine7 PE-Cyanine7

激发/发射光谱

569/780 nm 查看光谱

形式

Liquid

浓度

0.2 mg/mL

纯化类型

Affinity chromatography

保存液

PBS, pH 7.2

内含物

0.09% sodium azide

保存条件

4° C, store in dark, DO NOT FREEZE!

运输条件

Ambient (domestic); Wet ice (international)

RRID

AB_2573402

产品详细信息

Description: The eBioBV13 (BV13) monoclonal antibody reacts with mouse VE-Cadherin (CD144). VE-Cadherin is a 120 kDa member of the type II Cadherin family, characterized by the presence of 5 extracellular cadherin domains (ECD), and anchored to the actin cytoskeleton through their cytoplasmic tail. VE-Cadherin mediates homophilic adhesion between neighbouring endothelial cells and is localized within specialized structures at cell-cell contacts, called adherens junctions. VE-Cadherin is expressed constitutively throughout the entire vasculature, and is required for numerous endothelial cell functions including migration, survival, contact-dependent growth inhibition and endothelial cell assembly into tubular structures. Furthermore, it is thought that VE-Cadherin+CD45- cells from the yolk sac or aorta-gonad-mesonephros (AGM) have the potential to give rise to hematopoietic cells.

Applications Reported: This eBioBV13 (BV13) antibody has been reported for use in flow cytometric analysis.

Applications Tested: This eBioBV13 (BV13) antibody has been tested by flow cytometric analysis of bEnd.3 cells. This can be used at less than or equal to 0.125 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Light sensitivity: This tandem dye is sensitive to photo-induced oxidation. Please protect this vial and stained samples from light.

Fixation: Samples can be stored in IC Fixation Buffer (Product # 00-822-49) (100 µL of cell sample + 100 µL of IC Fixation Buffer) or 1-step Fix/Lyse Solution (Product # 00-5333-54) for up to 3 days in the dark at 4°C with minimal impact on brightness and FRET efficiency/compensation. Some generalizations regarding fluorophore performance after fixation can be made, but clone specific performance should be determined empirically.

Excitation: 488-561 nm; Emission: 775 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser.

Filtration: 0.2 µm post-manufacturing filtered.

靶标信息

VE-cadherin is a member of the cadherin superfamily that is located in a six-cadherin cluster in a region on the long arm of chromosome 16 and is involved in loss of heterozygosity events in breast and prostate cancer. VE-cadherin protein is a calcium-dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Functioning as a classic cadherin by imparting to cells the ability to adhere in a homophilic manner, VE-cadherin may play an important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. An alternative splice variant has been described but the full length sequence of VE-cadherin has not been determined.

仅用于科研。不用于诊断过程。未经明确授权不得转售。

How to use the Panel Builder

Watch the video to learn how to use the Invitrogen Flow Cytometry Panel Builder to build your next flow cytometry panel in 5 easy steps.

Product References

Knockout RAGE alleviates cardiac fibrosis through repressing endothelial-to-mesenchymal transition (EndMT) mediated by autophagy.

Cell death & disease

Zhang L,He J,Wang J,Liu J,Chen Z,Deng B,Wei L,Wu H,Liang B,Li H,Huang Y,Lu L,Yang Z,Xian S,Wang L

Published figure using CD144 (VE-cadherin) monoclonal antibody (Product # 25-1441-82) in Flow Cytometry

Tue May 11 00:00:00 EDT 2021

Characterization and origins of cell-free mitochondria in healthy murine and human blood.

Mitochondrion

Stephens OR,Grant D,Frimel M,Wanner N,Yin M,Willard B,Erzurum SC,Asosingh K

25-1441-82 was used in Flow cytometry/Cell sorting to identify whether intact, cell-free mitochondria from heterogeneous cellular sources are present in blood circulation under physiological conditions. To test this, circulating microparticles were analyzed using flow cytometry and proteomics.

Tue Sep 01 00:00:00 EDT 2020

Interleukin 35 Delays Hindlimb Ischemia-Induced Angiogenesis Through Regulating ROS-Extracellular Matrix but Spares Later Regenerative Angiogenesis.

Frontiers in immunology

Fu H,Sun Y,Shao Y,Saredy J,Cueto R,Liu L,Drummer C,Johnson C,Xu K,Lu Y,Li X,Meng S,Xue ER,Tan J,Jhala NC,Yu D,Zhou Y,Bayless KJ,Yu J,Rogers TJ,Hu W,Snyder NW,Sun J,Qin X,Jiang X,Wang H,Yang X

Published figure using CD144 (VE-cadherin) monoclonal antibody (Product # 25-1441-82) in Flow Cytometry

Fri Jul 09 00:00:00 EDT 2021

Role of Notch1 in the arterial specification and angiogenic potential of mouse embryonic stem cell-derived endothelial cells.

Stem cell research & therapy

Park JK,Lee TW,Do EK,Moon HJ,Kim JH

Published figure using CD144 (VE-cadherin) monoclonal antibody (Product # 25-1441-82) in Flow Cytometry

Wed Jul 18 00:00:00 EDT 2018

Single-cell transcriptomics reveals a new dynamical function of transcription factors during embryonic hematopoiesis.

eLife

Bergiers I,Andrews T,Vargel Bölükbaşı Ö,Buness A,Janosz E,Lopez-Anguita N,Ganter K,Kosim K,Celen C,Itır Perçin G,Collier P,Baying B,Benes V,Hemberg M,Lancrin C